Literature DB >> 30499739

Hydration requirements in patients receiving highly emetogenic chemotherapy.

Randy Erickson1, Neil Nebughr1, Michael C Mosier2, William Nibley3.   

Abstract

AIM: Chemotherapy-induced nausea and vomiting diminishes quality of life and increases healthcare resource use. This retrospective medical records analysis evaluated hydration requirements with emetogenic chemotherapy. PATIENTS &
METHODS: Cancer patients received moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC), and antiemetics palonosetron or granisetron extended-release subcutaneous (GERSC), neurokinin 1 receptor antagonist and dexamethasone. Unscheduled hydration event rates were determined.
RESULTS: For 186 patients (92 palonosetron, 94 GERSC) overall, mean hydration rate was significantly higher with palonosetron (0.6 vs 0.2; p = 0.0005). Proportion of patients with ≥1 hydration event was significantly higher with palonosetron overall (54 vs 33%; p = 0.0033) and in cycles 2-4 and the HEC subgroup.
CONCLUSION: GERSC within a three-drug antiemetic regimen may reduce unscheduled hydration requirements with MEC or HEC.

Entities:  

Keywords:  CINV; chemotherapy-induced nausea and vomiting; extended-release granisetron; highly emetogenic chemotherapy; hydration; moderately emetogenic chemotherapy; palonosetron

Mesh:

Substances:

Year:  2018        PMID: 30499739     DOI: 10.2217/fon-2018-0787

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  2 in total

1.  Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.

Authors:  Martin Barnes; George Calcanes; Michael C Mosier; Jeffrey Vacirca; Zulfiqar Malik
Journal:  Am Health Drug Benefits       Date:  2021-09

2.  Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.

Authors:  Martin Barnes; George Calcanes; Michael C Mosier; Jeffrey Vacirca; Zulfiqar Malik
Journal:  Am Health Drug Benefits       Date:  2021-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.